Abstract
Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Current Pharmaceutical Design
Title: Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET
Volume: 7 Issue: 18
Author(s): Frank Brady, Sajinder K. Luthra, Gavin D. Brown, Safiye Osman, Eric Aboagye, Azeem Saleem and Patricia M. Price
Affiliation:
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Abstract: Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Export Options
About this article
Cite this article as:
Brady Frank, Luthra K. Sajinder, Brown D. Gavin, Osman Safiye, Aboagye Eric, Saleem Azeem and Price M. Patricia, Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET, Current Pharmaceutical Design 2001; 7 (18) . https://dx.doi.org/10.2174/1381612013396907
DOI https://dx.doi.org/10.2174/1381612013396907 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World
Clinical Cancer Drugs Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies
Anti-Cancer Agents in Medicinal Chemistry Novel Action and Mechanism of Auranofin in Inhibition of Vascular Endothelial Growth Factor Receptor-3-Dependent Lymphangiogenesis
Anti-Cancer Agents in Medicinal Chemistry Effects of Polysaccharides from Selenium-enriched Pyracantha fortuneana on Mice Liver Injury
Medicinal Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Bottom-Up Proteomics
Current Analytical Chemistry Recent Advances and Challenges in Steroid Metabolomics for Biomarker Discovery
Current Medicinal Chemistry Synthesis of New Curcumin-like Pentadienones by O- and C-glycosylation
Current Organic Chemistry Inhibitors of Vascular Endothelial Growth Factor in Cancer
Cardiovascular & Hematological Agents in Medicinal Chemistry Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology An Optimised Radiolabel Procedure to Prepare 99mTc-Colloidal Rhenium Sulphide to Improve Radiochemical Purity
Current Radiopharmaceuticals Exploring the Bio-efficacies of Methanolic Extracts of Nostoc muscorum and Calothrix brevissima with their Characterization Using GC-MS
The Natural Products Journal A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Current Topics in Medicinal Chemistry Antitumoral Potential of Lansbermin-I, a Novel Disintegrin from Porthidium lansbergii lansbergii Venom on Breast Cancer Cells
Current Topics in Medicinal Chemistry Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacogenetics of Irinotecan
Current Medicinal Chemistry - Anti-Cancer Agents Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules
Current Pharmaceutical Design Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry